. 2017 Jan 1;8(1):29–38. doi: 10.7150/jca.16822

Table 3.

Selected molecular targeted therapy in clinical trials with SCLC.

Author	Target	Drugs	Phase	Results
Moore et al.⁽⁵³⁾	EGFR	Gefitinib	II	21% (1-year OS)
Dy et al.⁽⁵⁶⁾	C-kit	Imatinib	II	Arm A^a: 3.9 months (median OS)
Dy et al.⁽⁵⁶⁾	C-kit	Imatinib	II	Arm B^b: 5.3 months (median OS)
Spigel et al.⁽⁵⁷⁾	C-kit	Imatinib	II	8.4 months (median OS)
Spigel et al.⁽⁵⁷⁾	C-kit	Imatinib	II	5.4 months (median PFS)
Schneider et al.⁽⁵⁸⁾	C-kit	Imatinib	II	7.8 months (median OS)
Schneider et al.⁽⁵⁸⁾	C-kit	Imatinib	II	4.3 months (median PFS)
Miller et al.⁽⁵⁹⁾	C-kit	Dasatinib	II	17.0 weeks (median OS)
Miller et al.⁽⁵⁹⁾	C-kit	Dasatinib	II	5.9 weeks (median PFS)
Ellis et al.⁽⁶²⁾	IGF-1R	Dalotuzumab	I	67% (ORR)
Belani et al.⁽⁶³⁾	IGF-1R	EP vs. EP + V vs. EP + Cixutumumab	II	9.1 vs. 9.8 vs. 10.1 months (median OS, P<0.05)
Spigel et al.⁽⁶⁴⁾	VEGF	Bevacizumab	II	12.1 months (median OS)
Spigel et al.⁽⁶⁴⁾	VEGF	Bevacizumab	II	9.13 months (median TTP)
Ready et al.⁽⁶⁵⁾	VEGF	Bevacizumab	II	11.6 months (median OS)
Ready et al.⁽⁶⁵⁾	VEGF	Bevacizumab	II	7.0 months (median PFS)
Jalal et al.⁽⁶⁶⁾	VEGF	Bevacizumab	II	30.0 weeks (median OS)
Jalal et al.⁽⁶⁶⁾	VEGF	Bevacizumab	II	14.7 weeks (median PFS)
Trafalis et al.⁽⁶⁷⁾	VEGF	Bevacizumab	II	6.0 months (median OS)
Trafalis et al.⁽⁶⁷⁾	VEGF	Bevacizumab	II	3.0 months (median PFS)
Marcello et al.⁽⁶⁸⁾	VEGF	Bevacizumab + EP/EC vs. EP/EC	III	8.9 vs. 9.8 months (median OS, P= 0.113)
Marcello et al.⁽⁶⁸⁾	VEGF	Bevacizumab + EP/EC vs. EP/EC	III	5.7 vs. 6.7 months (median PFS, P = 0.03)
Han et al.⁽⁶⁹⁾	VEGF	Sunitinib	II	5.6 months (median OS)
Han et al.⁽⁶⁹⁾	VEGF	Sunitinib	II	1.4 months (median PFS)
Sharma et al.⁽⁷⁰⁾	VEGF	Sorafenibin	II	7.4 months (median OS)
Arnold et al.⁽⁷¹⁾	VEGF	Vandetanib vs. placebo	II	10.6 vs. 11.9 months (median OS, P= 0.90)
Arnold et al.⁽⁷¹⁾	VEGF	Vandetanib vs. placebo	II	2.7 vs. 2.8 months (median PFS, P = 0.51)
Ramalingam et al.⁽⁷²⁾	VEGF	Cediranib	II	6.0 months (median OS)
Ramalingam et al.⁽⁷²⁾	VEGF	Cediranib	II	2.0 months (median PFS)
Lee et al.⁽⁷³⁾	VEGF	EC + Thalidomide vs. EC + placebo	II	10.1 vs. 10.5 months (median OS, P= 0.28)
Owonikoko et al.⁽⁷⁶⁾	PARP1	Veliparib + EP	I	71.4 % (ORR)
Maria et al.⁽⁷⁷⁾	PARP1	TMZ + Veliparib vs. TMZ + placebo	II	8.2 vs. 7.0 months (median OS, P= 0.50)
Charles et al.⁽⁸⁰⁾	DLL3	Rova-T	II	8.0 months (median OS)^c

EGFR: epidermal growth factor receptor; PFS: progress free survival; IGF-1R: insulin-like growth factor-1 receptor; ORR: objective response rate; VEGF: vascular endothelial growth factor; TTP: time to progression; EP: etoposide-cisplatin; EC: etoposide-carboplatin; PARP1: Poly-(ADP-ribose) polymerase 1; TMZ: temozolomide; DLL3: Delta-like ligand 3; Rova-T: Rovalpituzumab tesirine;

^aDisease progression < 3 months after previous treatment.

^bDisease progression ≥3 months after previous treatment.

^cAmong patients with available archive tissue specimens and ≥ 50% of cells expressing DLL3.